NBRV News and Press, Nabriva Therapeutics plc From 12/20/19

-Nabriva anticipates a six-month review period by the Food and Drug Administration -CONTEPO is a potential first-in-class intravenous antibiotic in U.S. for the treatment of complicated urinary tract infections DUBLIN, Ireland, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc...

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Gary Sender...

S. pneumoniae continues to be designated by the CDC as “Serious Threat” underscoring need for rapid detection and prevention strategies, particularly in community setting   XENLETA™ has a novel mechanism of action that is different than all other antibiotics, ...

Nortech Systems (NASDAQ: NSYS ) +117%  after Q3 results . More news on: Nortech Systems Incorporated, 2U, Inc., Luckin Coffee Inc., Stocks on the move, Read more ...

Nabriva Therapeutics plc (NBRV) Q3 2019 Earnings Conference Call November 12, 2019 04:30 PM ET Company Participants Gary Sender - Chief Financial Officer Ted Schroeder - Chief Executive Officer Francesco Maria Lavino - Chief Commercial Officer Jennifer Schranz - Chief Medical O...

Gainers: CDLX   +20.8% . TWOU   +14.6% . DDOG   +14.2% . VRAY   +9.3% . NBRV   +8.4% . More news on: Cardlytics, Inc., 2U, Inc., Datadog, Inc., Stocks on the move, Read more ...

The following slide deck was published by Nabriva Therapeutics plc in conjunction with their 2019 Q3 earnings Read more ...

Nabriva Therapeutics (NASDAQ: NBRV ): Q3 GAAP EPS of -$0.24 beats by $0.04 . More news on: Nabriva Therapeutics plc, Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...

-More than 200 hospital formulary reviews of XENLETA™ scheduled before the end of the year- -Approximately 50% of all covered lives have outpatient formulary access to XENLETA- - Initiating focused community sales efforts for XENLETA- -Conference call today at 4:30 ...

DUBLIN, Ireland, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third-quarter 201...